The monitoring and evaluation of neurological symptoms using the Unified Wilson's Disease Rating Scale or the Global Assessment Scale for WD, as well as quantitative monitoring of blood biomarkers for central nervous system injury in WD (such as neurofilament proteins, glial fiber acid protein, tau proteins, and ubiquitin carboxyl terminal hydrolase L1), are effective methods for preventing early neurological deterioration (Ziemssen et al., 2022, 2023). This evidence concerns the gene MAPT and Wilson disease.